International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes have been proposed as a method of public health surveillance and are widely used in public health and clinical research. However, ICD-9-CM codes have been found to have variable accuracy for both health-care billing and disease classification, and they have never been comprehensively validated for use in public health surveillance. Therefore, the authors undertook a comprehensive analysis of the positive predictive values (PPVs) of ICD-9-CM codes for communicable diseases in 6 North Carolina health-care systems for the year 2003. Stratified random samples of patient charts with ICD-9-CM diagnoses for communicable diseases were reviewed and evaluated for their concordance with the Centers for Disease Control and Prevention surveillance case definitions. Semi-Bayesian hierarchical regression techniques were employed on the ensemble of disease-specific PPVs in order to reduce the overall mean squared error. The authors found that for the majority for diseases with higher incidence and straightforward laboratory-based diagnoses, the PPVs were high (>80%), with the important exception of tuberculosis, which had a PPV of 28.6% (95% uncertainty interval: 15.6, 46.5).
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, which are used on death certificates, in Medicaid records, and for hospital and outpatient discharge diagnoses, have been proposed as adjuncts to existing public health reporting systems (1) . In addition, ICD-9-CM codes are key data elements of the National Health Care Surveys, the National Ambulatory Medical Care Survey, the National Hospital Ambulatory Medical Care Survey, and the National Hospital Discharge Survey, which are commonly used for surveillance and research purposes (2) . The benefits of utilizing ICD-9-CM codes for surveillance and research are that they are standardized across health-care systems, applied in both outpatient and inpatient settings, easily accessed electronically, and designed to represent a patient's overall clinical diagnosis as the physician takes into account numerous clinical data (e.g., physical examination findings, laboratory findings, radiologic findings).
However, ICD-9-CM codes have been found to have variable accuracy for both health-care billing (3) and disease classification (4) because of both coding and physician errors. In an overall assessment of the accuracy of ICD-9-CM codes for Medicare claims data, Fisher et al. (4) found that diseases coded as infectious and parasitic diseases had 62.6%-65.4% agreement with the abstracted hospital data. In addition, the sensitivity of ICD-9-CM codes for 5 infectious diseases (shigellosis, salmonellosis, giardiasis, hepatitis A, and hepatitis B) studied at one medical center was estimated to be 53% (10/19) for inpatient cases and 7% (15/213) for outpatient cases (5) . Decreased sensitivity of ICD-9-CM codes in both inpatient and outpatient settings has been attributed to laboratory results' not being available at the time the patient visit was coded and more complex clinical diagnoses' being prioritized over infectious disease diagnoses.
In addition to potentially low sensitivity of ICD-9-CM codes for communicable disease surveillance, some disease codes may also have low positive predictive values (PPVs). One small validation study of ICD-9-CM codes for communicable disease surveillance found that 33% of outpatients and 35% of inpatients had their conditions incorrectly coded (6, 7) . An examination of the discordance between ICD-9-CM diagnostic codes and cases of active tuberculosis found several explanations for incorrect assignment of codes: the patient was suspected to have active tuberculosis at discharge, but the disease had not yet been confirmed; the patient had undergone screening (i.e., a tuberculin skin test) for evaluation of a latent tuberculosis infection; the patient had a history of treated tuberculosis; or the patient had an infection due to another species of Mycobacterium that was not included in the Mycobacterium tuberculosis complex (8, 9) . Despite these recognized concerns over low sensitivity and low PPVs of ICD-9-CM codes for communicable diseases, these codes have never been comprehensively validated for use in surveillance, though they continue to be utilized in both surveillance programs and clinical research studies. Therefore, we undertook a comprehensive validation study of the PPVs of ICD-9-CM codes used for communicable disease surveillance.
MATERIALS AND METHODS

Parent study
A retrospective cohort study was conducted in 8 large North Carolina nonfederal acute-care health-care systems that make up 32% of all inpatient visits and 23% of all outpatient visits in North Carolina (10) . The cohort study included both inpatients and outpatients who were assigned discharge diagnosis codes (ICD-9-CM codes) corresponding to communicable diseases that are reportable in North Carolina (see Web Table 1 , which is posted on the Journal's Web site (http://aje.oxfordjournals.org/)) during a 10-year period (from 1995-1997 to [2000] [2001] [2002] [2003] [2004] [2005] [2006] . Diseases were excluded if they were chronic infectious diseases (resulting in recurring assignment of a single ICD-9-CM code, such as human immunodeficiency virus), if no specific ICD-9-CM code was available (e.g., viral hemorrhagic fever), or if the North Carolina Department of Health and Human Services (DHHS) did not record patient identifiers in its surveillance database during the entire study time period (e.g., gonorrhea). Approval for the study was granted by the institutional review boards of all health-care systems as well that of the North Carolina DHHS.
Cases were matched from the health-care system ICD-9-CM records to the North Carolina DHHS surveillance database using a unique identifier created by either the Social Security number or a combination of the first 2 letters of the last name, the first letter of the first name, the date of birth, and a 2-digit disease code.
PPV study
Six of the health-care systems participating in the overall retrospective cohort study completed the PPV study. For each of these 6 health-care systems, a stratified random sample of cases with ICD-9-CM codes assigned in the year 2003 were selected for review, to estimate the PPV of ICD-9-CM codes for infectious diseases. Charts were stratified by health-care facility, by disease, and by matching status (i.e., whether the disease was reported to the North Carolina DHHS), and up to 5 charts or at least 20% were selected in each stratum.
Trained hospital-based public health epidemiologists at each facility reviewed these charts for their concordance with published Centers for Disease Control and Prevention (CDC) case classification criteria for surveillance purposes (11) . These epidemiologists perform case-finding activities using these CDC case classification criteria on a daily basis as part of their routine job duties. Each selected patient chart was classified as either a true reportable case (i.e., confirmed, suspect, or probable) or not a reportable case on the basis of specified laboratory, clinical, and/or epidemiologic case definition criteria in the CDC case definition. Unadjusted disease-specific PPVs were calculated on the basis of the number of ICD-9-CM coded patient diagnoses that were true cases according to the CDC criteria divided by the total number of ICD-9-CM coded patient charts that were reviewed. For each stratum, empirical continuity corrections were used when no true cases were found upon review (12) , and disease-specific data were aggregated across matching strata and health-care facilities with sample proportion weighting. Adjusted completeness proportions and 95% uncertainty intervals were calculated using semiBayesian hierarchical regression analysis (13, 14) , as Greenland and Robins (15) have recommended, to reduce the mean squared error when an ensemble of measures are estimated. ''Adjustment'' in this context refers to adjustment for multiple comparisons (15) .
This semi-Bayesian hierarchical regression analysis utilizes prior covariate data that help to explain the mean of the ensemble of estimates as well as a specified prior variance (s 2 ) of the distribution. The semi-Bayesian analysis uses the prior covariate data to help explain the differences between the PPVs found for different diseases. This is accomplished quantitatively by incorporating the covariate data for each disease into the hierarchical model and allowing each disease's mean PPV to be adjusted or shrunk to the overall mean PPV of each covariate group. Traditional maximum likelihood estimates (i.e., unadjusted estimates as presented here) can be viewed as a special case of semi-Bayesian analysis in which the prior variance is infinite. By specifying even a moderately informative prior variance such as a s 2 indicating that 95% of all completeness proportions lie between 0.4% and 90%, an appreciable reduction in the overall mean squared error can be expected with a shift in the point estimate and a narrowing of the 95% uncertainty interval for each PPV, with the relative degree of narrowing being greater for a disease with less information (i.e., a low number of charts available to review). A sensitivity analysis was conducted on the specified prior variance (s 2 ) using high, medium, and low s 2 values that assumed that 95% of the PPVs were within the ranges of 0.4%-99%, 0.4%-90%, and 16%-70%, respectively. Sensitivity analyses were also conducted on the inclusion or exclusion of prior covariates: whether or not the disease had a reportable laboratory result, had reportable serologic test results, and is rare in North Carolina (fewer than 10 reported cases statewide annually).
RESULTS
PPV study
A total of 670 charts were reviewed for 47 different diseases. Unadjusted and semi-Bayesian-adjusted disease-specific PPVs with 95% confidence intervals and 95% uncertainty intervals, respectively, are shown in Table 1 . Semi-Bayesian-adjusted PPVs ranged from 20.3% to 96.0%. Many of the higher-incidence (e.g., pertussis, invasive group A streptococcal infection, campylobacteriosis, shigellosis, and salmonellosis) and more severe (e.g., meningococcal meningitis and hemolytic uremic syndrome) diseases in North Carolina had PPVs exceeding 80%, although the PPV for tuberculosis was very low (PPV ¼ 28.6%, 95% uncertainty interval (UI): 15.57, 46.53). Marked differences between the unadjusted and adjusted point estimates were noted for Rocky Mountain spotted fever, Lyme disease, Haemophilus influenzae invasive disease, and acute hepatitis A; however, wide uncertainty intervals also reflected the imprecision in these estimates.
Sensitivity analyses
The sensitivity analysis of the s 2 values showed that the point estimates and uncertainty intervals were relatively Table continues insensitive to dramatic changes in s 2 . For example, for tuberculosis, with a low s 2 , the PPV was estimated as 34% (95% UI: 20, 51); with a medium s 2 , the PPV was 27% (95% UI: 15, 45%); and with a high s 2 , the PPV was 25% (95% UI: 13, 42%). However, the sensitivity analyses examining the use of prior covariates (Table 2) were shown to have dramatic effects on the point estimates for diseases with sparse data (e.g., Vibrio infection, cholera, measles) and produced minor changes for diseases with more data (e.g., salmonellosis, meningococcal meningitis).
DISCUSSION
Our findings suggest that ICD-9-CM codes for many communicable diseases of public health concern have PPVs that are high enough to be useful. One notable exception is tuberculosis, which had a low PPV of 28.6%, with relatively narrow precision (95% UI: 15.57, 46.53). Tuberculosis posed a particular problem with assignment of ICD-9-CM codes because of the difficulties with clinical diagnoses; that is, mycobacteria are slow-growing organisms, patients can be latently infected without having active disease, and patients are often started on empirical therapy until active tuberculosis can be ruled out because of the public health impact of a communicable airborne disease. Other diseases with low PPV estimates included unlikely or improbable diseases such as human rabies, hantavirus, poliomyelitis, smallpox, and plague; diseases which are relatively rare, such as measles, mumps, rubella, and Creutzfeldt-Jakob disease; and diseases which have complex surveillance case definitions, such as toxic shock syndrome. Hemolytic uremic syndrome also has a complex surveillance case definition, but it is almost always associated with isolation of Escherichia coli O157:H7, which may explain its higher PPV than that of toxic shock syndrome. Bayesian analyses have been shown in theory, simulation, and prediction problems to offer better estimates for measures as varied as baseball batting averages (16) and toxoplasmosis prevalence (15) . We believe that the semiBayesian-adjusted estimates offer improved overall accuracy and precision for our ensemble of PPV estimates. For example, for PPVs for which the maximum likelihood estimation methods result in 0% proportions, it is unlikely that the true PPV is actually 0%. The use of semi-Bayesian methods allows us to incorporate additional prior covariate data to produce results that are probably better and more plausible than maximum likelihood estimation results. However, for estimates that were based on less information, we still observed wide uncertainty intervals around the adjusted estimates.
Our sensitivity analysis showed that the rare-covariate model appeared to have results similar to those of the all-prior-covariate model, whereas the laboratory-covariate model appeared to have results similar to those of the no-prior-covariate model, and the serologic-covariate model appeared to produce unique results. Notably, to our knowledge, this is the first time in the published literature where the prior covariates have been shown to make a difference in the semi-Bayesian results. Based on the results of our sensitivity analysis for the prior covariates, we elected to use the model that included all prior covariates, since it allowed for more conservative estimates with a wider range of values. In addition, we chose a prior variance (s 2 ) that conservatively reduced the overall mean's likely 95% confidence interval from 0%-100% to 0.4%-90%.
The effect of semi-Bayesian analysis methods can be seen in the change in PPVs for Rocky Mountain spotted fever, Lyme disease, H. influenzae invasive disease, and acute hepatitis A. All of these diseases had relatively low PPVs (<25%) that increased to over 80% after semi-Bayesian adjustment, as they became adjusted or shrank towards the mean of their prior covariate groups (i.e., they are not rare diseases and have laboratory results). However, the imprecision of these estimates is still reflected in their wide uncertainty intervals. Furthermore, these diseases share similar properties with other low-PPV diseases in that their case definitions are complex and/or clinical diagnoses are difficult to make. Both Rocky Mountain spotted fever and Lyme disease require acute and convalescent serologic testing for confirmation of disease in order to meet the confirmed case definition. Invasive disease, including pneumonia, with H. influenzae requires isolation of the bacterium from a sterile body site, and positive hepatitis A serologic results indicating vaccination or a previous infection can be misinterpreted as an acute infection. Unlike tuberculosis, which had a low yet precise PPV, these diseases had more variability in their PPVs across hospital strata, which was reflected in their wide uncertainty intervals.
Despite the use of trained medical coders in health-care systems who review providers' documentation in order to assign the ICD-9-CM diagnosis codes following the patient's discharge or outpatient visit, these codes are not assigned without errors. Occasionally, we found ICD-9-CM codes that were mistakenly assigned for a similarsounding disease; for example, a patient who underwent head ultrasonography, abbreviated as HUS, was coded as having hemolytic uremic syndrome, or a patient with pleural plaques noted on a chest radiograph was assigned a diagnosis code for plague. Sometimes similar infectious diseases were mistakenly assigned-for example, hepatitis C instead of hepatitis A or monocytic ehrlichiosis instead of granulocytic ehrlichiosis. Finally, there were a few cases with no data in the medical record to support the diagnostic code. However, these situations occurred most often with rare or difficult-to-diagnose diseases. For diseases with complex case definitions-particularly in the outpatient setting, where specific diagnoses are often not availablefuture researchers should investigate the utility of broad syndrome-based ICD-9-CM codes rather than specific ICD-9-CM diagnostic codes.
This study may have been limited by the lack of availability of data on which to evaluate each case's concordance with CDC case definitions. While the CDC case definitions are standardized and utilized nationwide for communicable disease surveillance, some of the case definitions include complex criteria that are difficult to apply objectively to clinical cases. Each public health epidemiologist was trained to apply these case definitions as objectively as possible during the chart review in the PPV study, but misclassification of patients could have occurred because of incomplete clinical data in the patient's medical record or the interpretation of criteria for a complex case definition. However, a senior medical epidemiologist at the North Carolina DHHS was available to provide assistance with interpretation of complex case definition criteria and application to clinical or laboratory data.
To increase understanding of the utility of ICD-9-CM codes for infectious disease surveillance, additional comprehensive studies to estimate the sensitivity of ICD-9-CM codes are warranted. While, to our knowledge, this study constitutes the most comprehensive assessment to date of the PPVs of ICD-9-CM codes for infectious disease surveillance, we were not able to estimate the sensitivity of ICD-9-CM codes because of the cost and difficulties involved in identifying an appropriate gold standard. A previous study conducted by Watkins et al. (5) showed low ICD-9-CM sensitivity and used laboratory records as the gold standard for 5 laboratory-reportable diseases; however, this method is only appropriate for diseases with straightforward laboratory findings. Ideally, a complete medical record review would serve as a gold standard, but this would be both extremely costly and time-consuming and would be very inefficient for most of the infectious diseases with relatively low incidence rates in the general population. With estimates of both PPVs and the sensitivity of ICD-9-CM codes, not only can the utility of these codes be completely described but adjustment of ICD-9-CM code-based studies can be conducted using Bayes' Theorem (see the Web Appendix).
The standardized designation of ICD-9-CM codes to capture a patient's clinical diagnosis make them attractive data elements for automated, electronic disease surveillance. As new case definitions are developed to be compatible with automated, electronic public health surveillance, the utility of ICD-9-CM codes should be carefully considered. Our findings suggest that ICD-9-CM codes for communicable diseases have sufficiently high PPVs to be useful for diseases which are relatively common and have simple case definitions and clinical diagnoses. ICD-9-CM codes are inefficient for studying rare diseases (e.g., brucellosis, Q fever) or conducting surveillance for unlikely diseases (e.g., smallpox, anthrax) because of the high number of false-positive cases.
